Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH, Eliasson B, Dorresteijn JAN. Berkelmans GFN, et al. Among authors: dorresteijn jan. Eur Heart J. 2019 Sep 7;40(34):2899-2906. doi: 10.1093/eurheartj/ehy839. Eur Heart J. 2019. PMID: 30629157 Free PMC article.
Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.
Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw KT, Geisel MH, Lehmann N, Erbel R, Jöckel KH, van der Graaf Y, Verschuren WMM, Boer JMA, Nambi V, Visseren FLJ, Dorresteijn JAN. Jaspers NEM, et al. Among authors: dorresteijn jan. Eur Heart J. 2020 Mar 14;41(11):1190-1199. doi: 10.1093/eurheartj/ehz239. Eur Heart J. 2020. PMID: 31102402 Free PMC article.
Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness.
Hageman SHJ, Dorresteijn JAN, Bots ML, Asselbergs FW, Westerink J, van der Meulen MP, Mosterd A, Visseren FLJ; UCC-SMART Study Group; Asselbergs FW, Nathoe HM, de Borst GJ, Bots ML, Geerlings MI, Emmelot MH, de Jong PA, Leiner T, Lely AT, van der Kaaij NP, Kappelle LJ, Ruigrok YM, Verhaar MC, Visseren FLJ, Westerink J. Hageman SHJ, et al. Among authors: dorresteijn jan. Eur J Prev Cardiol. 2022 Mar 30;29(4):635-644. doi: 10.1093/eurjpc/zwab028. Eur J Prev Cardiol. 2022. PMID: 34009323
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.
Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, Bhatt DL, Steg PG, Läll K, Mägi R, Gynnild MN, Ellekjær H, Saltvedt I, Tuñón J, Mahíllo I, Aceña Á, Kaminski K, Chlabicz M, Sawicka E, Tillman T, McEvoy JW, Di Angelantonio E, Graham I, De Bacquer D, Ray KK, Dorresteijn JAN, Visseren FLJ. Hageman SHJ, et al. Among authors: dorresteijn jan. Eur Heart J. 2022 May 7;43(18):1715-1727. doi: 10.1093/eurheartj/ehac056. Eur Heart J. 2022. PMID: 35165703 Free PMC article.
109 results